data microarray raw data (ATCC)
Structured Review

Data Microarray Raw Data, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 552 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+microarray+raw+data/pm38261515-228-138-152?v=ATCC
Average 96 stars, based on 552 article reviews
Images
1) Product Images from "Circulating tumor cells reveal early predictors of disease progression in patients with stage III NSCLC undergoing chemoradiation and immunotherapy."
Article Title: Circulating tumor cells reveal early predictors of disease progression in patients with stage III NSCLC undergoing chemoradiation and immunotherapy.
Journal: Cell reports
doi: 10.1016/j.celrep.2024.113687
Figure Legend Snippet: Figure 1. Overview of CTC isolation and characterization summary (A) Schematic of CTC isolation using microfluidic graphene oxide (GO) chips. Each sample is processed on two devices, one for enumeration via immunoflu- orescent staining and the second for mRNA microarray analysis. The CTC characteristics are then used generate profiles that are predictive of progression-free survival. (B) The timeline of patient sample draws shown; the black time points indicate no treatment, the blue time points are during chemoradiation therapy, and green time points are during durvalumab for most patients.
Techniques Used: Isolation, Staining, Microarray
Figure Legend Snippet: Figure 4. mRNA microarray data demonstrate altered gene expression profiles of CTCs during chemoradiation treatment (A) Unbiased clustering heatmap of top 50 differentially expressed genes by log fold change. Sample time points and patient outcome are labeled in the top rows. Patient IDs are also labeled on the bottom of the heatmap. In the right-hand annotation columns, each gene is recorded as being found in the literature to cause the given effect, including proliferation, invasion, and metastasis. See also Table S6. (B) Select genes with normalized expression for pre-TX and week 4 time points alongside healthy controls. (C) Fold change for 7 genes between pre-TX and week 4 time points that were differentially expressed in patients with sustained stable disease. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Techniques Used: Microarray, Gene Expression, Labeling, Expressing

